Industry Affiliation and Position on the Rosiglitazone Controversy

Authors with industry links were more likely to have positive views about rosiglitazone's risk profile.

Controversy followed the mid-2007 publication of two articles on rosiglitazone within weeks of each other in the New England Journal of Medicine. In the first — a meta-analysis (JW Gen Med May 24 2007) — rosiglitazone was associated with elevated risk for myocardial infarction (MI) in patients with type 2 diabetes. In the second — an interim analysis of a randomized controlled trial (JW Gen Med Jun 12 2007) — rosiglitazone was not associated with elevated MI risk. Now, in a systematic review, investigators identified 202 articles published through April 2009 that addressed either of these two reports and assessed the relation between authors' conflicts of interest and their positions on the association between rosiglitazone and MI.

Only 53% …

Reviewing Author

Paul S. Mueller, MD, MPH, FACP

Disclosures

Nothing to disclose

Paul S. Mueller, MD, MPH, FACP

Disclosures

Nothing to disclose

Industry Affiliation and Position on the Rosiglitazone Controversy

Topics

Reviewing Author